Ventrus BioSciences Completes Enrollment of Pivotal Phase 3 Trial of Diltiazem in Patients With Anal Fissures

by Eddie Staley, Benzinga Editor
December 21, 2011 3:02 PM | 20 seconds read |
Ventrus BioSciences, Inc. VTUS announced that S.L.A. Pharma has completed patient enrollment and randomization in the first Phase 3 clinical trial of Diltiazem (VEN 307) in patients with anal fissures. Initial top-line data from the Phase 3 study is expected to be available in May 2012. Ventrus Biosciences has licensed the North American rights to diltiazem hydrochloride cream from S.L.A. Pharma.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!